Real-world data show that Enhertu benefits those with HR+ breast cancer, whereas Trodelvy is effective as an initial treatment for HER2-null/HER2– disease.

Gilead has tagged Trodelvy as a cornerstone of its ambition to have a third of its revenue from oncology by 2030. The TROP2-targeted antibody-drug conjugate was the centerpiece of Gilead’s $21 ...

In Trodelvy’s FDA-approved indication of metastatic triple-negative breast cancer (TNBC), the anti-TROP-2 drug cut the risk of disease progression by 59% over chemotherapy in patients who had ...

Trodelvy (sacituzumab govitecan-hziy) is a brand-name drug prescribed for certain breast cancers. It’s given as an intravenous (IV) infusion by a healthcare professional. The dosage can vary ...

An accelerated approval for Gilead Sciences’ cancer drug Trodelvy could be in question after the company disclosed Thursday afternoon that a confirmatory trial failed to meet its main objective ...

Trodelvy (sacituzumab govitecan), the standard treatment for triple-negative breast cancer, offers hope for improved survival, but comes with the challenge of managing side effects, as an expert ...

“Trodelvy has the potential to become a cornerstone treatment in metastatic urothelial cancer, and we are excited about the expected results from the ongoing Phase 3 TROPiCS-04 study that may ...

Trodelvy is the first and only approved Trop-2-directed antibody-drug conjugate (ADC) that has demonstrated meaningful survival advantages in two different types of metastatic breast cancers ...

Gilead's (GILD) Trodelvy with Merck's (MRK) Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

– First Pivotal Phase 3 Trial to Show Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care in 1L Metastatic TNBC – – Early Trend in Improvement in ...

Trodelvy is currently approved in more than 50 countries for second-line or later mTNBC patients and in several countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer.